In the following video, Motley Fool health-care analyst David Williamson continues his look at the top-performing health-care stocks of this past January, by highlighting the biggest winner of the month, Keryx (KERX +0.00%). The stock exploded this month, shooting up 247%, although David reminds us that this was possible only because of the stock's starting point after the share price collapsed last year, when a cancer drug it shared with Aeterna Zentaris (AEZS +0.00%) failed its phase 3 trial. David tells us about the new drug in Keryx's pipeline that is crushing its trial endpoints, and how the new drug compares with its competition.
January Top 10: Keryx
By Dave Williamson – Feb 5, 2013 at 5:30PM
NASDAQ: KERX
Keryx Biopharmaceuticals

A look back at January's most incredible health-care stocks.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid